Compass Pathways Plc ADR
Suletud
12.09 5.68
Ülevaade
Aktsiahinna muutus
24h
Min
12
Max
12.23
Sissetulek | 185M 91M |
|---|---|
Aktsiakasum | -0.3 |
Töötajad | 156 |
EBITDA | 139M 93M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +94.54% upside |
Järgmine tulemuste avaldamine | 30. juuli 2026 |
|---|
Turukapital | 211M 1.5B |
|---|---|
Eelmine avamishind | 6.41 |
Eelmine sulgemishind | 12.09 |
Compass Pathways Plc ADR Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
